OUR MISSION

Phages have a proven ability to target and kill bacteria, something they show us in nature every day. So, there is an imperative to explore how phage-based pharmaceuticals can add to our arsenal of weapons in the defense against bacterial infections

Phages have a proven ability to target and kill bacteria, something they show us in nature every day. So, there is an imperative to explore how phage-based pharmaceuticals can add to our arsenal of weapons in the defense against bacterial infections

Our mission at PhagoMed is to bring phage therapy to patients as fast as possible – in indications where phages can have a big impact on the treatment pathways and, ideally, become (part of) the first line therapy.

One of the most obvious application fields of phages are in treating bacterial biofilms. These biofilms are hard to treat with antibiotics even when the bacteria are not drug resistant. Phages have a strong ability to degrade the extracellular matrix that surrounds the bacteria in the biofilm and could therefore be superior to antibiotics in several biofilm-related settings.

One of the most obvious application fields of phages are in treating bacterial biofilms. These biofilms are hard to treat with antibiotics even when the bacteria are not drug resistant. Phages have a strong ability to degrade the extracellular matrix that surrounds the bacteria in the biofilm and could therefore be superior to antibiotics in several biofilm-related settings.

Our initial pipeline is therefore focused on these biofilm-forming infections. The goal is always the same: to develop robust phage-based pharmaceuticals that can be validated in clinical trials and be applied to patients. As fast as possible.

If you want to learn more, explore what phages are, look at our pipeline, meet our team or simply contact us.